Clinical trial
A Study of the Safety and Efficacy of Golimumab in Patients With Active…
NCT00265096 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00265096 |
|---|---|
| Title | A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis |
| Acronym | GO-REVEAL |
| Lead sponsor | Centocor, Inc., Industry |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis, Psoriatic |
| Intervention type | Biological |
| Interventions | golimumab, Placebo |
| Enrollment | 407 |
| Start date | Dec 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | Jan 1, 2012 |
| First posted | Dec 14, 2005 |
| Last update posted | Jul 19, 2013 |
| Countries | Belgium, Canada, Poland, Spain, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: